Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial

Fig. 2

Immunohistochemical staining for AR (a), ERα (b) and ERβ (c) in the tissue sections from the same area of a patient with PC. Strong (a) or moderate (b and c) staining was identified in the nuclei of cancer cells. The LI of AR (a), ERα (b) and ERβ (c) in cancer cells was 100, 35.4 and 26.4, respectively. Scale bar =100 μm

Back to article page
\